Related Experiment Video

Updated: Jun 19, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Global drug development in cancer: a cross-sectional study of clinical trial registries

B Seruga1, P C Hertz1, L W Le1

  • 1Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|October 10, 2009
PubMed
Abstract

Insights

Cancer drug development focuses on profitable cancers in more developed regions (MDR). Cancers prevalent in less developed regions (LDR) like stomach and liver need more research focus for equitable drug development.

Area of Science:

  • Oncology
  • Clinical Trials
  • Global Health Disparities

Background:

  • Cancer drug development is expensive and may prioritize cancers prevalent in more developed regions (MDR).
  • Significant disparities exist in cancer research focus between more developed regions (MDR) and less developed regions (LDR).

Purpose of the Study:

  • To analyze cancer drug development trends in relation to cancer type and geographic location.
  • To investigate the correlation between clinical trial registration and cancer burden (incidence, mortality, prevalence) in MDR and LDR.

Main Methods:

  • A review of phase II and III clinical trials for new cancer drugs registered between January and June 2008.
  • Correlation analysis between the number of clinical trials and cancer data from GLOBOCAN 2002, stratified by global region.

Main Results:

  • 399 new trials were identified, with 57% industry-sponsored. Breast, lung, prostate, and colorectal cancers were most studied.
  • In MDR, trial numbers strongly correlated with cancer incidence, mortality, and prevalence.
  • In LDR, only cancer prevalence showed a significant association with the number of trials.

Conclusions:

  • Drug development efforts should increase for lethal cancers disproportionately affecting less developed regions (LDR).
  • Cancers such as stomach, liver, and esophageal cancers require greater emphasis in future drug development strategies.

More Related Videos

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...